Spinal anaesthesia and general anaesthesia do not confer an increased risk of mortality in hip fracture patients, leaving anaesthetists free to choose which is the most clinically appropriate for individual patient situations
ID
Bron
Verkorte titel
Aandoening
postoperative mortality, at 30 days
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
30 day mortality
Achtergrond van het onderzoek
Machine learning algorithm based analysis and logistical regression analysis of data from the Australian and New Zealand Hip Fracture Registry. This should be about 4000 patients. This data shall be examined to see if there is an impact on type of anaesthesia (spinal, general or both) and user a regional technique on 30 day mortality. This high quality database has never previously been analysed for these outcomes with logistical regression and machine learning.
Doel van het onderzoek
Spinal anaesthesia and general anaesthesia do not confer an increased risk of mortality in hip fracture patients, leaving anaesthetists free to choose which is the most clinically appropriate for individual patient situations
Onderzoeksopzet
date of surgery, 30 day mortality, discharge from hospital
Onderzoeksproduct en/of interventie
Analysis to determine significance of type of anaesthesia and use of regional anaesthesia on 30 day mortality
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
data from patients with a hip fracture and who underwent a surgical repair with either spinal, general anaesthesia or both in the ANZHFR.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
data deemed too heterogenous
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9325 |
| Ander register | METC FMC : 41.21 |